Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments 中文版
4 Dec, 2017 (Monday)

            
BOSIDENG(3998)
Analysis:
Bosideng International Holdings (3998) is gradually moving towards the transition from a traditional business model that focuses on wholesale to a retail model that attaches greater importance to the needs of consumers. With regard to its branded down apparel business, the Group has endeavored to clear inventory and adjust the sales network. Current inventory has returned to a healthy level and the layout of sales network has become more reasonable. As for non-down apparel business, the Group`s ladieswear business has been expanded through acquisitions and the Group has gradually built up a high-end ladieswear platform. In terms of OEM management business, the Group`s Vientnam factory, under cooperation with ITOCHU Corporation, is expected to commence normal production in early 2018, which will contribute to a steady expansion of OEM management business in the future. (I do not hold the above stock)
Strategy:
Buy-in Price: $0.66, Target Price: $0.73, Cut Loss Price: $0.62

TRAD CHI MED(570)
Analysis:
The company reported revenue/net profit of RMB3.89bn/662mn (+21.88%/21.59%). We see future growth momentums coming from quick development of CTCMG (Concentrated TCM granules), sales growth in non-TCM hospitals and synergies from integrated value chain. CTCMG are distributed by individual packages and medicine dispensing machines. The revenue through medicine dispensing machine dramatically increased by 65.7% YoY in 1H17. As to 30 June, 3072 machines have been installed in 1740 hospitals. As the machine forms a natural entry barrier for other competitors and charges a high switching cost to the hospitals, we expect future sales growth given the progressive installation of medicine dispensing machines. Meanwhile, we estimate the market for CTCMG to open up in future, which means that the company is allowed to enter more non-TCM hospitals to offer CTCMG and dispensing machines. We also expect productive synergies with its integrated value chain in future. In 2016, the company completed the acquisition of TCM decoction pieces firms, which contributes to extension of up-stream business and enhances control of raw materials for CTCMG and TCM decoction pieces. The company continues to upgrade construction line and build new capacity. For downstream, the company completed the acquisition of 60% registered capital in Guizhou Tongjitang Pharmacy Chain, thus further expands sales network.
Strategy:
Buy-in Price: $4.21, Target Price: $5.70, Cut Loss Price: $3.65


LK (600388.SH) - In the first three quarters, the results of were solid, with large shareholders completing the overweight

Summary of Investment

- Major shareholders increased their holdings, and the margin of safety appeared;

- The wide market space in the non-electric field is urgently needed to be released;

Investment Rating

As an industry leader, the company will certainly benefit from the promising market space for future non-electric treatment sector. We forecast that the company's net income for 2017-2018 will be RMB732 million and RMB815 million, respectively; EPS will be RMB0.69 and RMB0.76, respectively; equivalent to the PE ratio in 2017/2018 of 23.0/20.7. We give a target price of RMB20.0 for “Buy” rating. (Closing price as at 30 Nov 2017)

Steady Growth in the First Three Quarters

Longking was listed in 2000 and is the first listed company in the field of environmental protection equipment manufacturing in China. The company's main products include flue gas dust collection, FGD, SNCR, electrical control equipment, and bulk material conveying, which are widely used in the air pollution control of electric power, building materials, metallurgy, chemical industry and light industry. In 2016, the revenue of the company exceeded RMB8 billion for the first time. In 2012-2016, the revenue composite growth of the company was 17.3%, and the compound growth rate of net profit attributable to the parent company recorded 22.9%. The company recorded sustainable growth.

Longking recorded a revenue of RMB4.971 billion, up by 0.86% yoy, a net profit attributable to parent company of RMB470 million, up by 9.59% yoy, and 11.87% yoy after deduction of non-recurring profit and loss. Equivalent earnings per share were RMB0.44. The figure was RMB0.4 in the same period of last year. Specifically, Q1, Q2 and Q3 reported revenues of RMB1.14 billion, RMB1.81 billion and RMB2.01 billion, respectively, and net profits of RMB84 million, RMB142 million and RMB245 million, respectively. Profits are in line with expectation.

Gross Margin and Net Profit Margin Increased

The gross margin in the period was 26.1%, up 1.81% from 24.29% in the same period of last year. Net profit margin 9.56%, up by 0.81% yoy, in which the quarterly net profit margin in the third quarter reached 12.19%, a sharp rise from the previous two quarters. The period cost rate was 14.59%, up 1 ppts yoy, in which the financial expense rate was up 161.5% yoy, to RMB23.56 million.

Net Operational Cash Flow Expected to Be Positive for the Year

The net operational cash flow in the first three quarters was RMB-283 million, which was slightly improved from the mid-period of RMB-356 million. The net operational cash flow will very probably be positive. The company's account receivable RMB2.026 billion, down from RMB2.147 billion of the beginning of the year. Advances received were RMB6.483 billion, up RMB510 million compared with the beginning of the year. Capital on paper reached RMB1.448 billion, down RMB1.1 billion from the start of the year, mainly because of the repayment of RMB500 million medium-term note and an increase in the net operating cash expenditure.

Sufficient Orders In Hand, Leading Flue Gas Dust Collection Technology

The company added RMB7.8 billion of orders in the first three quarters, with RMB2.6 billion added in the third quarter. By the end of the third quarter, the orders in hand reached RMB18.1 billion. With sufficient orders in hand, sustained growth of results is guaranteed. At present, the peak of investment in thermal power industry has passed, and the newly-added scale of coal-fired power generating units is limited. There is only a certain increment of space for the ultra-low emission transformation of the existing units. With the gradual enhancement of the national policy on the emission standards of non-electric sectors such as steel and chemical industry, the demand for air treatment in the non-electric fields will soon be increased. The company has been in the market for many years, especially in the R&D of atmospheric management technology. In 2016, the R&D expenditure was RMB395 million, accounting for 4.9 percent of operating revenue. In 2016, the market share of flue gas dust collection products ranked first in the country. We believe that the solid technical reserve and R&D capability will help the company to win the first place in the market of non-electric atmosphere management.

Major Shareholders Increased Their Holdings

After changes in share options are completed, Sunshine Group holds indirectly 17.17% stock rights (183.5 million shares) of Longking by holding directly 51% stock rights of Eastright Investment & Development. In July, Sunshine Group increased its holdings of 30,284,000 shares through the trust scheme, with the shareholding ratio increased to 20%. In November, Sunshine Group continued to increase its holdings of 32,520,000 shares, with the shareholding ratio increased to 23.04%. At present, the accumulative increased amount reached RMB965 million, with an increase of about 62.8 million shares, accounting for 5.87% of the total share capital. According to estimation, Sunshine Group shares average at RMB18.8/share, and the current price has a higher margin of safety.

Risk Warnings

The bids of new units and large units in power industry reduce;

The market competition of non-electric field is fierce;

The market is not expanding as expected;

Industry policy risk;

Financials

Click Here for PDF format...




Recommendation on 4-12-2017
RecommendationBuy
Price on Recommendation Date$ 15.750
Suggested purchase priceN/A
Target Price$ 20.000
Writer Info
Wang Yannan
(Research Analyst)
Tel: 86 21 51699400-107
Email:
wangyannan@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2017 Phillip Securities (HK) Ltd. All Rights Reserved.